Global Pituitary Cancer Market Research Report: By Cancer Type (Adrenocorticotropic Hormone-Secreting [ACTH] Tumor, Growth Hormone-Secreting Tumor, Prolactin-Secreting Tumor and Thyroid-Stimulating Hormone-Secreting Tumor), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and others), End User (Hospitals & Clinics, Research & Academic Institutes and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

Market Scenario

Pituitary Cancer Market is expected to register significant growth over the forecast period. The market is projected to register a 5.7% CAGR over the forecast period. Pituitary cancers occur in the pituitary gland that is located beyond the nose. Factors such as the rising prevalence of pituitary cancer are expected to drive market growth. Moreover, the increasing research and development expenditure in the field of oncology for the development of innovative drugs to treat cancer is also expected to boost the market growth.

However, the side effects of the treatment and stringent government regulations are expected to hamper the market growth. 

Segmentation

The Global Pituitary Cancer Market has been segmented into Cancer Type, Treatment Type, End User, and Region.

Based on cancer type, the global pituitary cancer market has been segmented into adrenocorticotropic hormone-secreting (ACTH) tumor, growth hormone-secreting tumor, prolactin-secreting tumor, and thyroid-stimulating hormone-secreting tumor.

The global pituitary cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and others. The surgery segment is further segmented into endoscopic trans nasal transsphenoidal surgery and craniotomy. The radiation therapy segment is further segmented into stereotactic radiosurgery, external beam radiation, intensity-modulated radiation therapy (IMRT), and proton beam therapy.

The global pituitary cancer market, by end user, has been segmented into hospitals & clinics, specialty clinics, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The pituitary cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European pituitary cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 

The pituitary cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The Middle East & Africa pituitary cancer market has been segmented into the Middle East and Africa.

Key Players

Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Mylan N.V. (US), Johnson & Johnson Services, Inc. (US), Onxeo (France), Ipsen Pharmaceuticals (France), Salix Pharmaceuticals, Inc. (US), and Strides Pharma Science Limited (India) are some of the key players operating in the global pituitary cancer market.

Regional Market Summary

Global Pituitary Cancer Market Share (%), by Region, 2018  

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to dominate the global pituitary cancer market owing to the rising prevalence of pituitary cancer and presence of major market players in the region, such as Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., and Pfizer Inc.

Europe is expected to hold the second-largest share of the pituitary cancer market owing to the presence of major market players such as AstraZeneca, Novartis AG, GlaxoSmithKline plc, Onex, and Ipsen Pharmaceuticals, among others. Moreover, rising R&D activities for the development of advanced treatment options for pituitary cancer is also expected to drive the market growth.

Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing awareness regarding various types of cancer, including pituitary cancer, growing incidence rate of Pituitary cancer and increasing R&D in the field of oncology.

The pituitary cancer market in the Middle East & Africa is expected to register slow growth during the forecast period owing to the lack of awareness regarding cancer.

Global Pituitary Cancer Market, by Cancer Type

• Adrenocorticotropic Hormone-Secreting (ACTH) Tumor


• Growth Hormone-Secreting Tumor


• Prolactin-Secreting Tumor


• Thyroid-Stimulating Hormone-Secreting Tumor

Global Pituitary Cancer Market, by Treatment Type

• Surgery


• Endoscopic Transnasal Transsphenoidal Surgery


• Craniotomy


• Radiation Therapy


• Stereotactic Radiosurgery


• External beam radiation


• Intensity Modulated Radiation Therapy (IMRT)


• Proton Beam Therapy


• Chemotherapy


• Others

Global Pituitary Cancer Market, by End User

• Hospitals and Clinics


• Specialty Clinics


• Others

Global Pituitary Cancer Market, by Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  

• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Intended Audience

• Biotechnology companies


• Research institutes


• Medical device companies


• Pharmaceutical companies


• Hospitals and clinics


• Ambulatory surgical centers


• Academic institutes


• Government organizations

Report Scope:

Report Attribute/Metric	Details
Market Size	2025: Significant Value
CAGR	5.7% (2019-2025)
Base Year	2019
Forecast Period	2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Cancer Type, Treatment Type, End User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Mylan N.V. (US), Johnson & Johnson Services, Inc. (US), Onxeo (France), Ipsen Pharmaceuticals (France), Salix Pharmaceuticals, Inc. (US), and Strides Pharma Science Limited (India)
Key Market Opportunities	New product launches and R&D Amongst major key Players
Key Market Drivers	The Rising prevalence of pituitary cancer are expected to drive market growth

Frequently Asked Questions (FAQ) :

---